his.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effectiveness of Digitoxin and Pembrolizumab (Keytruda) in inhibiting human glioblastoma T98G cell viability in vitro
University of Skövde, School of Health and Education.
2019 (English)Independent thesis Basic level (degree of Bachelor), 20 credits / 30 HE creditsStudent thesis
Abstract [en]

Background: Glioblastoma multiforme is the most destructive brain cancer that nowadays continues to overcome all therapies. According to the resistance of glioblastoma to current therapies and the revolution that cardiac glycosides and anti-PD1 therapies have meant in many cancers, human T98G cell line of glioblastoma was chosen to conduct cell viability assays in vitro.

Methods: Changes in the viability of T98G glioblastoma cells treated with different concentrations of Digitoxin and Pembrolizumab, single or combined, were evaluated by MTS assays. This project allowed testing for possible synergistic effect of both drugs with combined therapies. The AmplexTM Red Kit was used to measure the release of reactive oxygen species by T98G cells treated with Digitoxin and Pembrolizumab either as single doses or combined. The expression of the PD-1, PD-L1, and PD-L2 genes from cells treated with these drugs individually or in combination was quantified by a Real-Time qPCR.

Results: Digitoxin treatment showed a reduction in cell viability for the 100 nM concentration after 48 and 72h incubation. Pembrolizumab was effective in inhibiting cell growth for concentrations ranging between 0.5-100 mg/L after 24, 48 and 72h of exposure but only 0.5 mg/L after 48h and 100 mg/L after 48 and 72h of incubation were significant. Combinations of these drugs did not show a synergistic effect. Moreover, a decrease in ROS levels and overexpression of PD-1, PD-L1 and PD-L2 genes were seen after single and combined therapies of both drugs.

Conclusion: Results support both drugs as potential chemotherapeutic agents to suppress the proliferation of human T98G glioblastoma cells. Overall, Pembrolizumab might become a better anticarcinogenic therapy than Digitoxin.

Place, publisher, year, edition, pages
2019. , p. 27
Keywords [en]
Glioblastoma T98G cell line, cell viability, in vitro, Digitoxin, Pembrolizumab, ROS, PD-1, MTS assay, qPCR, Amplex-Red assay
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:his:diva-17742OAI: oai:DiVA.org:his-17742DiVA, id: diva2:1355996
Subject / course
Biomedicine/Medical Science
Educational program
Biomedicine - Study Programme
Supervisors
Examiners
Available from: 2019-10-07 Created: 2019-09-30 Last updated: 2019-10-07Bibliographically approved

Open Access in DiVA

No full text in DiVA

Search in DiVA

By author/editor
Salus Villena, Raquel
By organisation
School of Health and Education
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

urn-nbn

Altmetric score

urn-nbn
Total: 27 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf